A box of Plaquenil, an anti-malaria drug hydroxychloroquine made by Sanofi, used for years to treat malaria and autoimmune disorders.
Alain Pitton | NurPhoto | Getty Images
Hydroxychloroquine, the drug backed by President Donald Trump to combat Covid-19, is no better than a placebo in preventing infection of the coronavirus, according to results expected to be published Wednesday in the New England Journal of Medicine.
The study, the first randomized, placebo-controlled trial, which is considered the “gold standard” in science, looked at 821 people in the United States and Canada who had been exposed to the coronavirus. About 12% of the people who were given the malaria drug developed Covid-19, compared to 14% who did not receive the drug, according to the study’s findings.
The study was led by Dr. David Boulware, an infectious disease researcher at the University of Minnesota.
The coronavirus, which